Shukla's First Space Message: ‘Orbiting the Earth. Jai Hind, Jai Bharat'
His message, relayed fr m the SpaceX Dragon spacecraft following separation from the Falcon 9 upper stage, marked a historic return to human spaceflight for India, 41 years after Rakesh Sharma's iconic mission in 1984. "Namaskar, my dear countrymen! What a ride! We are back in the space once again after 41 years. It's an amazing ride. We are revolving around the Earth at a speed of 7.5 kilometres per second.
The Tiranga embossed on my shoulders tells me that I am with all of you. This journey of mine is not a beginning to the International Space Station (ISS) but to India's Human Space Programme. I want all of you to be part of this journey. Your chest, too, should swell with pride...Together, let's initiate India's Human Space Programme. Jai Hind! Jai Bharat!" Group Captain Shukla said from space.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
15 minutes ago
- The Hindu
NISAR Mission: Satellite will be placed in orbit by Indian rocket, says ISRO chief
The Indian Space Research Organisation (ISRO) is gearing up for a major milestone with the launch of the NISAR (NASA-ISRO Synthetic Aperture Radar) mission on July 30, 2025. According to Dr. V. Narayanan, Chairman of ISRO and Secretary of the Department of Space, the satellite will be placed in orbit by an Indian rocket. While speaking to reporters on Friday (July 25, 2025), Dr. Narayanan said, 'On the 30th of July, we are going to have the NISAR mission. The satellite will be placed in orbit by the Indian rocket...' ISRO said that it will launch the NISAR, the first joint Earth observation satellite by ISRO and NASA, from the Satish Dhawan Space Centre in Sriharikota, Andhra Pradesh, on July 30 at 5:40 p.m. Additionally, ISRO stated that the satellite would provide high-resolution, day-and-night, all-weather data by scanning the entire world every 12 days, identifying minute variations in the Earth's surface, such as vegetation dynamics, ice sheet shifts, and ground deformation. 'The mission will support many critical applications, including sea ice monitoring, ship detection, storm tracking, soil moisture changes, surface water mapping, and disaster response. A milestone in over a decade of collaboration between ISRO & NASA/JPL,' it added. According to ISRO, the NISAR satellite, weighing 2,392 kg, will be injected into a 743 km Sun-synchronous orbit with an inclination of 98.40 degrees. Equipped with dual-frequency Synthetic Aperture Radar—NASA's L-band and ISRO's S-band—NISAR features a 12-metre unfurlable mesh reflector antenna integrated into ISRO's modified I3K satellite bus. Utilising SweepSAR technology for the first time, the satellite will offer a 242 km swath with high spatial resolution, enabling comprehensive Earth observation. 'NISAR, weighing 2392 kg, is a unique Earth observation satellite and the first satellite to observe the Earth with a dual-frequency Synthetic Aperture Radar (NASA's L-band and ISRO's S-band), both using NASA's 12m unfurlable mesh reflector antenna, integrated to ISRO's modified I3K satellite bus. NISAR will observe Earth with a swath of 242 km and high spatial resolution, using SweepSAR technology for the first time,' ISRO stated in a press release. NISAR's ability to provide high-resolution, all-weather data every 12 days will support critical applications, from tracking climate change impacts to aiding disaster management. 'The satellite will scan the entire globe and provide all weather, day and night data at 12-day intervals and enable a wide range of applications. NISAR can detect even small changes in the Earth's surface, such as ground deformation, ice sheet movement and vegetation dynamics. Further applications include sea ice classification, ship detection, shoreline monitoring, storm characterisation, changes in soil moisture, mapping & monitoring of surface water resources and disaster response,' the release added.
Time of India
an hour ago
- Time of India
Mark Zuckerberg appoints Shengjia Zhao, who co-created OpenAI's ChatGPT, as chief scientist of Meta's AI Superintelligence Lab
Facebook co-founder and Meta CEO Mark Zuckerberg has announced that Shengjia Zhao , co-creator of OpenAI 's ChatGPT , will serve as the chief scientist of Meta Superintelligence Labs. Zhao was one of several strategic hires in Zuckerberg's multi-billion-dollar hiring spree and investment in artificial intelligence (AI). Zhao, whose name was initially listed among new hires in a June memo, was revealed by Zuckerberg as a co-founder of Meta Superintelligence Labs and its "lead scientist from day one." 'Now that our recruiting is going well and our team is coming together, we have decided to formalize his leadership role,' he added. Zhao will report directly to Zuckerberg and Alexandr Wang , the former CEO of Scale AI , who is now Meta's chief AI officer. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Buy Resmed AirSense 11 with flat 20% off ResMed Buy Now Undo "Shengjia has already pioneered several breakthroughs including a new scaling paradigm and distinguished himself as a leader in the field," Zuckerberg shared in a social media post, adding, "I'm looking forward to working closely with him to advance his scientific vision." "The next few years are going to be very exciting!" Zuckerberg concluded in his post. Zhao co-created ChatGPT, GPT-4, mini models, 4.1 and o3 In addition to co-creating ChatGPT, Zhao has played an instrumental role in developing GPT-4 , mini models, 4.1, and o3, as per CNBC. He also previously led synthetic data efforts at the AI research company. Meanwhile, Wang said on X, 'We are excited to announce that @shengjia_zhao will be the Chief Scientist of Meta Superintelligence Labs! Shengjia is a brilliant scientist who most recently pioneered a new scaling paradigm in his research. He will lead our scientific direction for our team.' Meta spends billions into hiring and acquiring AI talent In recent months, Meta has spent billions of dollars hiring AI talents from Google, OpenAI, Apple and Anthropic. He also acquired ScaleAI for $14 billion and made its CEO Meta's chief AI officer. Zuckerberg also said the company will spend hundreds of billions of dollars on building huge AI data centres in the US. 7 Reasons that make Samsung GALAXY Z FLIP7 different from others
Hans India
an hour ago
- Hans India
Study links common diabetes drug with cardiovascular risk
New Delhi: A commonly used type 2 diabetes medication in the US -- Glipizide -- may be linked to a higher rate of heart-related conditions, claimed a study. Researchers from Mass General Brigham examined nationwide data from nearly 50,000 patients treated with different sulfonylureas. They found that glipizide was linked to a higher incidence of heart failure, related hospitalisation, and death compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. The findings are published in JAMA Network Open. 'Patients with type 2 diabetes are at heightened risk of adverse cardiovascular incidents such as stroke and cardiac arrest,' said corresponding author Alexander Turchin, Division of Endocrinology at Brigham and Women's Hospital (BWH). 'While sulfonylureas are popular and affordable diabetes medications, there is a lack of long-term clinical data on how they affect cardiac health in comparison to more neutral alternatives like dipeptidyl peptidase 4 inhibitors,' he added. Type 2 diabetes is a common chronic disease whose prevalence continues to grow worldwide. Individuals with Type 2 diabetes have an increased risk of adverse cardiovascular events, including coronary ischemia, stroke, and heart failure. Mitigation of cardiovascular risk is therefore an important aspect of the treatment of diabetes. The study included 48,165 patients with type 2 diabetes and moderate cardiovascular risk who received care at 10 different study sites across the country. The researchers studied the five-year risk of major adverse cardiovascular events in patients treated with different sulfonylureas (glimepiride, glipizide, or glyburide) or DPP4i in addition to metformin, a primary diabetes medication. They found that glipizide was associated with a 13 per cent increase in cardiovascular risk when compared to DPP4i, while glimepiride and glyburide led to relatively smaller and less clear effects, respectively. 'Our study underscores the importance of evaluating each drug in a particular pharmacological class on its own merits,' said Turchin. The team also called for further research to uncover the underlying mechanisms.
